^{By Aline Goby}

‍

The Life Sciences sector is facing a profound shift that has intensified in recent years: innovations are becoming increasingly ambitious—from gene therapies and robotic surgery to personalized medicine—yet the ability of organizations to industrialize, document, and bring these to market on time is subject to growing complexity. Regulatory pressure, the rapid evolution of requirements, and the increasing density of projects create friction points that can delay market entry.

It is against this backdrop that agap2 Life Sciences has structured its offering: expertise forged through direct contact with manufacturers, shaped by their real-time challenges in light of industry developments. It is organized around every stage of the product lifecycle, taking into account the scientific, regulatory, industrial, and digital dimensions specific to a healthcare project.

‍

From lab to plant: mastering the critical path to market launch

The development of a healthcare product does not end with the demonstration of scientific feasibility in R&D. A critical phase follows when it becomes necessary to replicate what worked at the pilot scale within an industrial production environment, subject to Good Manufacturing Practices (GMP), raw material variability, and site-specific operational constraints.
‍

A process mastered at a small scale does not guarantee the same performance in industrial production. During scale-up, Critical Process Parameters (CPPs) may behave differently, making the process more sensitive to variations. Deviations not anticipated during the design phase can have a direct impact on production and lead to delays in market launch. This scale-up process, well known to manufacturers, remains one of the major challenges in product development and industrialization.

‍

"Industrialization is not just a technical transposition of R&D results. It is an intrinsic component of development that requires the scientific, regulatory, and operational dimensions to be aligned from the outset. The earlier this alignment occurs, the better production risks are controlled."

‍

At agap2 Life Sciences, we choose to anticipate rather than correct: from the study and R&D stages, we integrate qualification strategy and IQ/OQ/PQ requirements directly into the healthcare product design, so that validation becomes a performance lever rather than a final administrative burden.

‍

‍

For example, as part of the expansion of the Novo Nordisk site in Chartres, which aimed to double aseptic production capacity, our teams were involved from the early stages of the project. They optimized the design of weighing isolators, participated in the selection of mobile tank suppliers, and structured key quality documents, including the Validation Plan (VPL) and the Project Quality Master Plan (PQMP).
‍

By anticipating quality requirements from the design phase, this work reduced the risk of production discrepancies, limited the need for subsequent re-qualification, and ensured a smooth transition to industrial scale within the set deadlines.

‍

Turning regulatory compliance into a strategic performance driver

MDR, IVDR, IEC 62304, 21 CFR Part 11, GDPR, AI Act: the regulatory landscape for Life Sciences is evolving at a rapid pace, creating new challenges for quality and regulatory teams. Integrating compliance from the design stage offers a significant operational advantage over an approach handled at the end of a project.
‍

Health authorities no longer just expect a documented file. They evaluate the maturity of the quality system, the traceability of decisions, and the consistency of technical choices throughout the product lifecycle. Organizations capable of anticipating these requirements gain agility, credibility, and the ability to adapt to regulatory changes.

‍

"Compliance has become a factor of credibility and competitiveness. Organizations that structure it early gain robustness and peace of mind in the face of changing regulatory frameworks."

‍

‍

agap2 Life Sciences supports the structuring and optimization of quality systems, the validation of computerized systems, and the securing of Data Integrity processes. The goal: to build a robust and sustainable framework capable of meeting current requirements while adapting to future regulatory developments.
‍

For example, we worked with LYRA ETK (Euroteknika) before any non-compliance occurred to structure their entire MDR technical file (classes I, IIa, and IIb): risk analyses, UDI labeling, and validation of electronic instructions for use (eIFU). This proactive approach secured product registrations, reduced the risk of audit observations, and established an evolving documentation framework capable of absorbing future regulatory updates.
‍

Similarly, at ThermoFisher Patheon, we defined the site's overall validation strategy in advance, managed the qualification of equipment and utilities, and upgraded quality documentation prior to GMP certification. By anticipating potential discrepancies, we not only secured the certification but also strengthened the maturity of the quality system for future inspections.

‍

Sustainable industrial performance: excellence beyond volume

Industrial performance is no longer measured by production speed alone. It now encompasses the reduction of non-conformities, process reliability, energy optimization, and the ability to maintain consistent production over time. A site that produces quickly but with a high scrap rate is neither profitable nor competitive.

In addition to these operational challenges, ESG requirements are transforming industrial modernization into a key strategic lever.

‍

"Industrial performance is no longer just about producing faster. It is also measured by the ability to reduce waste, manage energy, and ensure process reliability. A competitive site is, above all, a stable and controlled one."

‍

agap2 Life Sciences works on facility modernization projects, new construction, and the qualification of critical infrastructure, combining process engineering, regulatory compliance, and operational management.
‍

This is the case, for example, at Christian Dior, where our teams addressed a 40% scrap rate on an automated pouring line. By conducting an in-depth analysis of critical process parameters, performing design of experiments, and characterizing product defects through physicochemical analysis, we reduced this rate to 15%, stabilized production start-ups, and significantly improved the line's overall performance.
‍

This same structured approach was applied at Biospringer, where we managed new construction projects at a food processing site: 3D modeling, supplier coordination, and HSE compliance. The result: modernized facilities, controlled budgets and timelines, and strengthened environmental compliance, directly meeting the group's ESG requirements.

‍

Digital transformation: the rigor of the pharmaceutical industry applied to software

Digital technology is profoundly reshaping the Life Sciences sector: medical software, document automation, industrial system interconnection, and the use of health data. However, this transformation must take place within a particularly demanding regulatory framework.
‍

Computerized system validation, cybersecurity, and data integrity are now priority areas for inspection. Authorities do not evaluate the sophistication of a solution, but rather an organization's ability to demonstrate control over its lifecycle. Integrating these requirements from the design phase helps secure technological innovation while mitigating risks during validation or audit phases.

‍

"The digitalization of healthcare systems cannot be treated as simple technological upgrades: they require the same methodological rigor as a health product, with structured validation, controlled risk management, and compliance considered from the very start of the transformation project."

‍

‍

agap2 Life Sciences integrates validation, traceability, and cybersecurity requirements into its clients' digital projects from the design stage, ensuring that technological innovation is also compliant innovation.
‍

This is particularly the case at eCential Robotics, where our teams contributed to migrating a critical C++ solution to a secure micro-services web architecture within a demanding MedTech environment. The project included a .NET Core backend, a React frontend with WebAssembly, and the implementation of a CI/CD pipeline using GitLab. Code coverage increased from 0% to 83%, significantly strengthening the software quality and robustness of the solution.

‍

Global expertise serving the entire health product lifecycle.

In Life Sciences, performance no longer relies on isolated expertise, but on the ability to coordinate multiple skill sets throughout the product lifecycle. From R&D to market launch, consistency between scientific, regulatory, industrial, and digital challenges is a decisive factor in securing projects and accelerating innovation.
‍

"Our added value does not lie solely in technical expertise. It lies in our ability to connect challenges, anticipate critical interfaces, and secure the entire project trajectory, from R&D to market."

‍

‍In a sector where regulatory requirements are intensifying and projects are becoming increasingly complex, this integrated approach becomes a true driver of performance.

Innovation in healthcare is no longer limited to discovery. It requires comprehensive mastery. That is precisely where agap2 Life Sciences.

‍

Do you have a Life Sciences project? Whether it's industrialization, regulatory compliance, digital transformation, or operational performance: contact us !

‍

‍

‍

ABOUT ALINE

Holding an MBA in International Management from ISEG and a Master's degree from the International School of Management, Aline began her career in business development, notably at Mars and SC Johnson, where she gained solid experience in account management and commercial strategy.

In 2017, she joined agap2 and shifted her focus to the Life Sciences sector, gradually advancing to the position of Department Manager, then Key Activity Manager, working closely with pharmaceutical, medical device, and biotechnology companies. Now a Senior Key Activity Manager, she leads the development of agap2 Life Sciences in France and Europe, by structuring strategic collaborations with key players in the healthcare industry.

Passionate about innovation and compliance challenges in the sector, she is committed to making agap2 a benchmark partner for manufacturers in the healthcare and food industries.

‍